UltraGreen ai (ULG) investor relations material

Business and clinical value

• ICG fluorescence supports real-time surgical visualization; cited benefits include 300% better identification of biliary structures in laparoscopic cholecystectomy and fewer colorectal anastomotic leaks.

• Enabled 7M+ surgeries since 2015 and has a presence in 55 countries.

• ICG is available across leading robotic and tower imaging systems and is endorsed by global surgical societies.

Market opportunity and adoption

• ~10M annual procedures across key indications; 2025 use of ~987K vials represented <10% penetration, with market growth of ~10–12% annually.

• Europe holds 94.4% market share; ROW revenue rose 36% YoY to $30.5M in 9M2026 and 41% YoY to $31.0M in FY2025.

• By 26 Oct 2026, publications were up 13%, cumulative trials 31%, KOLs 71%, IC-Flow approvals 70% and Verdye-approved countries 75% since FY2024.

• 3Q2026 milestones included Verdye approval in South Africa, IC-GREEN/Verdye approval in 42 countries, and US FDA orphan drug designation for liver cancer imaging.

Growth strategy

• Priorities include sustaining US leadership, expanding ICG beyond hospitals, and broadening the offering with imaging systems, software and new clinical applications.

• Strategy extends fluorescence imaging from operating theatres into outpatient clinics, then wound care and community settings using more accessible systems.

• Commercial models combine camera placement with ICG starter packs and maintenance, camera leasing, and software subscriptions or per-use applications.

• NIR camera market entry targets FDA 510(k) clearance and EU Class IIa MDR, followed by applications in diabetic foot, vascular assessment, reconstruction and wound care.